Shamim Kazmi-Stokes

Gene-expression profiling of bortezomib added to standard chemoimmunotherapy for diffuse large B-cell lymphoma (REMoDL-B): an open-label, randomised, phase 3 trial

Andrew Davies, Thomas Cummin, Sharon Barrans et al. · The Lancet Oncology · 2019 · 272 citations · Full text

Medicine, Hematology, Oncology +15

A Phase I Trial of AT9283 (a Selective Inhibitor of Aurora Kinases) in Children and Adolescents with Solid Tumors: A Cancer Research UK Study

Lucas Moreno, Lynley V. Marshall, Andrew D.J. Pearson et al. · Clinical Cancer Research · 2014 · 56 citations

Medicine, Oncology, Pharmacology +17

DIFFERENTIAL EFFICACY OF BORTEZOMIB IN SUBTYPES OF DIFFUSE LARGE B‐CELL LYMPHOMA (DLBL): a PROSPECTIVE RANDOMISED STUDY STRATIFIED BY TRANSCRIPTOME PROFILING: REMODL‐B

Andrew Davies, Sharon Barrans, Tom Maishman et al. · Hematological Oncology · 2017 · 17 citations · Full text

Medicine, Hematology, Oncology +17

A first-in-human phase I study to determine the maximum tolerated dose of the oral Src/ABL inhibitor AZD0424

Victoria K. Woodcock, Sally Clive, Richard H. Wilson et al. · British Journal of Cancer · 2018 · 11 citations · Full text

Pharmacy, Pharmacokinetics, Pharmacology +9